AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 223.12B |
| Revenue (ttm) | 48.11B |
| Net Income (ttm) | 7.06B |
| Shares Out | n/a |
| EPS (ttm) | 4.52 |
| PE Ratio | 31.59 |
| Forward PE | 17.14 |
| Dividend | 2.91 (2.02%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 15,737 |
| Average Volume | 506 |
| Open | 143.50 |
| Previous Close | 144.75 |
| Day's Range | 143.30 - 144.55 |
| 52-Week Range | 113.25 - 148.50 |
| Beta | n/a |
| RSI | 60.76 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies
Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.
Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns
Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU
Top Research Reports for AstraZeneca, RTX & Applied Materials
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure
AstraZeneca hails major breakthroughs with breast-cancer drugs
An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time.
AstraZeneca: CHMP Recommends Saphnelo For Approval
(RTTNews) - AstraZeneca (AZN) said its Saphnelo or anifrolumab has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patients with systemi...
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway
AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu
AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu
AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial
AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial
Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment
Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment
AZN: Promising Results from DESTINY-Breast11 Phase III Study
AZN: Promising Results from DESTINY-Breast11 Phase III Study
Top global stories this week: AstraZeneca, Taiwan Semiconductor Manufacturing among notable names
US stock indexes ended the week higher, supported by encouraging earnings reports from major U.S. banks.
AstraZeneca's Datroway extends survival in aggressive breast cancer
AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for...
AstraZeneca : ENHERTU Shows Significant Survival Benefit In DESTINY-Breast05 Phase III Trial
(RTTNews) - AstraZeneca announced that the Phase III DESTINY-Breast05 trial demonstrated ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improves invasive disease-free survival (IDFS) in patie...
AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials
AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.
Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation
(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment for inadequately control...
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.
AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis
AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis
Amgen, AstraZeneca gets FDA nod for Tezspire
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years ...
US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.
AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects
AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects
Astra, GSK up after report on U.K. – U.S. drug pricing deal
AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.